Updates on p53: modulation of p53 degradation as a therapeutic approach.
The p53 pathway is aberrant in most human tumours with over 50% expressing mutant p53 proteins. The pathway is critically controlled by protein degradation. Here, we discuss the latest developments in the search for small molecules that can modulate p53 pathway protein stability and restore p53 activity for cancer therapy.
Dey
A
A
Department of Cell Cycle Control, Institute of Molecular and Cell Biology, 61, Biopolis Drive, 03-05 Proteos, Singapore 138673, Singapore.
Verma
C S
CS
Lane
D P
DP
D000818:Animals; D006801:Humans; D009369:Neoplasms / Q000378:metabolism* / Q000628:therapy; D051736:Proto-Oncogene Proteins c-mdm2 / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
D016159:Tumor Suppressor Protein p53; D051736:Proto-Oncogene Proteins c-mdm2